Acumen pharmaceuticals to participate in the ubs biopharma conference

Charlottesville, va., nov. 02, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the ubs biopharma conference on thursday, nov. 9, 2023 at 10:00 a.m. et. the live webcast may be accessed under the investors tab on www.acumenpharm.com and will be archived for 90 days.
ABOS Ratings Summary
ABOS Quant Ranking